We are pleased to introduce Abd Tahrani as the new Editor in Chief for European Endocrinology. In this interview Dr Tahrani discusses his research interests and his aims for the journal over the next year.
FILMED AT THE EUROPEAN ASSOCIATION FOR THE STUDY OF DIABETES (EASD) ANNUAL MEETING, SEPTEMBER 2016
COULD YOU TELL US A LITTLE ABOUT YOURSELF AND YOUR CAREER TO DATE?
00:19 - My name is Abd Tahrani. I’m a National Institute for Health Research Clinician Scientist at the University of Birmingham and an Honorary Consultant Physician in Diabetes and Endocrinology and Obesity at Heart of England NHS Foundation Trust. I’m also the lead for weight management research and diabetic neuropathy at Heart of England NHS Foundation Trust. My career started in the UK in the year 2000 when I did my general training, which was completed by obtaining MRCP(UK) in 2003. Then after that, I joined the specialty of Diabetes Endocrinology and Obesity and continued my training until I finished and obtained CCT in Diabetes and Endocrinology in 2012. During that time, I obtained a Master’s in Medical Sciences from Keele University and I also obtained my PhD at the University of Birmingham. Following that, I also obtained a special certification in Obesity Education and Prevention from the World Obesity Federation, and I was also awarded their National Fellowship.
WHAT ARE YOUR MAIN RESEARCH INTERESTS?
01:26 – My main research is focussed on four main areas. The first area is the metabolic impact of sleep-related disorders, particularly in the fields of diabetes, obesity and vascular disease. My second main area is understanding the pathogenesis and developing new treatments for diabetes-related microvascular complications. My third area is developing obesity management, and that extends from lifestyle interventions to bariatric surgery. And finally, I have a major interest in the pharmacology of type 2 diabetes.
WHAT DO YOU CONSIDER THE MOST EXCITING DEVELOPMENTS IN THE DIABETES FIELD OVER THE PAST YEAR?
02:09 - Over the past year, there have been several landmark studies published, particularly in relation to the cardiovascular outcome studies, including LEADER, EMPA-REG, and in this conference, we’ll hear more about SUSTAIN. And I think these studies have resulted in major developments in the way we treat patients with diabetes in terms of reducing their cardiovascular risk, as well as improving or reducing the risk of development of nephropathy.
WHAT DO YOU CONSIDER THE GREATEST STRENGTH OF EUROPEAN ENDOCRINOLOGY?
02:45 - The greatest strength of European Endocrinology is that it has a very distinguished editorial pool that has leading investigators of international reputation and they are leaders in their field. It has also published very high-quality articles written by leaders in the field of diabetes and endocrinology and obesity. In addition, it’s open access format which allows the articles to be easily available at the time of publication to the research community and the public.
WHAT ARE YOUR AIMS FOR THE JOURNAL OVER THE NEXT YEAR?
03:20 – Over the next year, I look forward to working with my colleagues at European Endocrinology. We will mainly focus on increasing the multimedia content and will work also with the Editorial Board to increase the variety of submissions which will be published in European Endocrinology.